Abstract
Advancing age presents a major challenge for the elderly population in terms of quality of life. The risk of cognitive impairment, motor in-coordination, and behavioral inconsistency due to neuronal damage is relatively higher in aging individuals of society. The brain, through its structural and functional integrity, regulates vital physiological events; however, the susceptibility of the brain to aging-related disturbances signals the onset of neurodegenerative diseases. Mitochondrial dysfunctions impair bioenergetic mechanism, synaptic plasticity, and calcium homeostasis in the brain, thus sufficiently implying mitochondria as a prime causal factor in accelerating aging-related neurodegeneration. We have reviewed the fundamental functions of mitochondria in a healthy brain and aimed to address the key issues in aging-related diseases by asking: 1) What goes wrong with mitochondria in the aging brain? 2) What are the implications of mitochondrial damage on motor functions and psychiatric symptoms? 3) How environmental chemicals and metabolic morbidities affect mitochondrial functions? Further, we share insights on opportunities and pitfalls in drug discovery approaches targeting mitochondria to slow down the progression of aging and related neurodegenerative diseases.
Keywords: Mitochondria, Aging, membrane permeability, Synaptic plasticity, neuropsychiatric symptoms, metabolic morbidity, biomarkers.
Current Drug Targets
Title:Aging of Brain Related with Mitochondrial Dysfunctions
Volume: 22 Issue: 14
Author(s): Vipin Dhote*, Prem Samundre, Aditya Ganeshpurkar and Aman Upaganlawar
Affiliation:
- Faculty of Pharmacy, VNS Group of Institutions, Department of Pharmacology, Bhopal,India
Keywords: Mitochondria, Aging, membrane permeability, Synaptic plasticity, neuropsychiatric symptoms, metabolic morbidity, biomarkers.
Abstract: Advancing age presents a major challenge for the elderly population in terms of quality of life. The risk of cognitive impairment, motor in-coordination, and behavioral inconsistency due to neuronal damage is relatively higher in aging individuals of society. The brain, through its structural and functional integrity, regulates vital physiological events; however, the susceptibility of the brain to aging-related disturbances signals the onset of neurodegenerative diseases. Mitochondrial dysfunctions impair bioenergetic mechanism, synaptic plasticity, and calcium homeostasis in the brain, thus sufficiently implying mitochondria as a prime causal factor in accelerating aging-related neurodegeneration. We have reviewed the fundamental functions of mitochondria in a healthy brain and aimed to address the key issues in aging-related diseases by asking: 1) What goes wrong with mitochondria in the aging brain? 2) What are the implications of mitochondrial damage on motor functions and psychiatric symptoms? 3) How environmental chemicals and metabolic morbidities affect mitochondrial functions? Further, we share insights on opportunities and pitfalls in drug discovery approaches targeting mitochondria to slow down the progression of aging and related neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Dhote Vipin *, Samundre Prem , Ganeshpurkar Aditya and Upaganlawar Aman , Aging of Brain Related with Mitochondrial Dysfunctions, Current Drug Targets 2021; 22 (14) . https://dx.doi.org/10.2174/1389450121999201209202247
DOI https://dx.doi.org/10.2174/1389450121999201209202247 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcription Factors as Therapeutic Targets in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Cerebral White Matter Injuries Following a Hypoxic/Ischemic Insult During the Perinatal Period: Pathophysiology, Prognostic Factors, and Future Strategy of Treatment Approach. A Minireview
Current Pharmaceutical Design Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Cyclophilin D as a Drug Target
Current Medicinal Chemistry Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design Serotonin 5-HT6 Receptor Antagonists for the Treatment of Alzheimers Disease
Current Topics in Medicinal Chemistry Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders
Current Molecular Pharmacology Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Granulocyte Colony-Stimulating Factor Attenuates Blood-Brain Barrier Damage and Improves Cognitive Function in Spontaneously Hypertensive Rats
CNS & Neurological Disorders - Drug Targets Deep Neck Infections: Decisional Algorithm for Patients with Multiple Spaces Involvement
Reviews on Recent Clinical Trials Dimethyl-Carbamic Acid 2,3-Bis-Dimethylcarbamoyloxy-6-(4-Ethyl-Piperazine- 1-Carbonyl)-Phenyl Ester: A Novel Multi-Target Therapeutic Approach to Neuroprotection
Medicinal Chemistry Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets An Update of Patents, Preclinical and Clinical Outcomes of Lipid Nanoparticulate Systems
Current Pharmaceutical Design Amyloid-beta Induced Neurotoxicity Impairs Cognition and Adult Hippocampal Neurogenesis in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research RNA Sensors as a Mechanism of Innate Immune Evasion among SARSCoV2, HIV and Nipah Viruses
Current Protein & Peptide Science Prediction of Mutations in H3N2 Hemagglutinins of Influenza A Virus from North America Based on Different Datasets
Protein & Peptide Letters Conference Report (8th Annual Meeting of the Society for the Study of Neuroprotection and Neuroplasticity)
CNS & Neurological Disorders - Drug Targets Gene-Gene Interactions in a Context of Individual Variability in Antipsychotic Drug Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Biomarkers of Protein Oxidation in Human Disease
Current Molecular Medicine